INVO Bioscience Reports Second Quarter 2021 Financial and Operating Results and Provides Business Update

Rhea-AI Summary

INVO Bioscience, Inc. (Nasdaq: INVO) reported Q2 2021 financial results, showing revenues of $208,472, down from $246,072 in Q2 2020. The net loss was approximately $(1.8) million, increasing due to higher expenses. Key operational milestones included the opening of the first U.S. INVO Center in Birmingham, Alabama, and joint ventures to establish additional centers in Atlanta and Monterrey, Mexico. The company emphasizes its commitment to democratizing fertility treatment and aims to capture a larger share of the market with new center operations.

Positive

• Opened first U.S.-based INVO Center in Birmingham, Alabama, exceeding patient appointment expectations.
• Joint venture agreement to open an INVO Center in Atlanta, Georgia, in September 2021.
• Expansion of operations with a clinic in the San Francisco Bay area through a partnership with Lyfe Medical, LLC.
• New appointment of Barbara Levy as SVP, enhancing leadership in global clinical integration.

Negative

• Revenue decreased by approximately 15% from Q2 2020 to Q2 2021, attributed to lower product sales.
• Net loss increased to approximately $(1.8) million, up from $(1.3) million in Q2 2020, due to rising operating expenses.
• Selling, general, and administrative expenses rose significantly to approximately $2.0 million.

SARASOTA, Fla., Aug. 16, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo culture system, today announced financial and operating results for the second quarter ended June 30, 2021 and provides a business update.

Recent Operational Highlights

• Officially opened the first U.S.-based INVO Center, located in Birmingham, Alabama in partnership with reproductive specialists Dr. Nicholas Cataldo, MD, MPH, Dr. Karen R. Hammond, DNP, CRNP, and Lisa Ray, MS, ELD. The new Birmingham practice, named "Innovative Fertility Specialists, an INVO Center" will provide fertility treatment utilizing the efficient, effective, and affordable INVOcell option. The practice has begun seeing patients and expects to perform initial treatment cycles in September 2021.
• Signed a joint venture agreement with Bloom Fertility to open an INVO Center in Atlanta, Georgia. Led by reproductive specialist Dr. Sue Ellen Carpenter, M.D., the center is scheduled to open in September 2021.
• Completed the site build-out and preparing to open the Company's INVO Center JV in Monterrey, Mexico, Positib Fertility, with Drs. Francisco Arredondo and Ramiro Ramirez. Expected to open in the October timeframe.
• Signed a partnership agreement with Lyfe Medical, LLC to establish and operate a clinic in the San Francisco Bay area to offer the INVO procedure. Lyfe Medical will own the clinic while INVO will set-up and manage an embryology center to provide laboratory services to the clinic and its patients in exchange for a share of the clinic's revenue.
• Expanded capabilities within the global OB/GYN vertical with the appointment of Barbara Levy, M.D., FACOG, FACS as the SVP, global clinical integration. Dr. Levy is considered one of the most influential reproductive health clinical executives in the world, recently serving as Vice President, Health Policy at the American College of Obstetricians and Gynecologists (ACOG) and chair of the American Medical Association/Specialty Society Relative Value Scale Update Committee.
• Appointed Andrea Goren as CFO, replacing the Company's past utilization of an outside CFO consulting firm, to lead the Company's finance function and to support the execution of the Company's strategic business plan, including the operational launch of the Company's INVO Center joint ventures.

Financial Highlights

• Revenues were $208,472 for the quarter ended June 30, 2021, compared to $246,072 for the quarter ended June 30, 2020.
• Net loss for the second quarter of 2021 was approximately $(1.8) million, which included approximately $(0.7) million of non-cash charges primarily related to the debt discount amortization and equity-based compensation.
• Adjusted EBITDA for the second quarter of 2021 was $(1.3) million, which included $93,969 of JV start-up costs, compared to $(0.8) million in the prior year's second quarter (see Adjusted EBITDA Table).
• As of June 30, 2021, the Company had a cash position of approximately $6.6 million.

Management Discussion

"Our team made excellent progress during the second quarter of 2021 toward our key objectives, headlined by last week's official opening of our first INVO Center practice in Birmingham, Alabama," commented Steve Shum, CEO of INVO Bioscience.  "We feel INVO is now well positioned for success based on the following core foundational elements developed over the past 2 years:

1. Our Team – An experienced internal operating team with key positions filled, a strong and diverse board of directors, a scientific advisory board composed of well-known and respected fertility industry experts, and key outside KOL's/consultants.
2. Our Partners – A growing list of quality distributors around the world, experienced and motivated JV Partners, and a committed shareholder base.
3. Our Technology – We have gained valuable real market usage data (and hence further validation) along with a clear understanding of how our technology "fits" in the industry and the key challenges it helps solve.

We believe there is a substantial underserved patient population with infertility challenges and a real need to expand access to treatment. In our opinion, this is a multi-billion-dollar market expansion opportunity, and INVOcell is well positioned to address the unmet medical need."

"The new Birmingham practice, our very first INVO Center, is a major milestone and one of the most significant in the Company's history to date.  The center is already off to an encouraging start as we have surpassed our internal expectations for patient appointments and expected treatment cycles planned for the first month. The vision to drive accelerated adoption of the INVOcell solution while also increasing much needed capacity and patient access within the fertility industry is coming to reality with this first INVO Center, thanks to the expertise and commitment of our internal team and partners."

Mike Campbell, COO further added, "With the blueprints now firmly in place for our INVO Center model, we are rapidly moving towards the opening of centers in Atlanta, Monterrey, Mexico and the San Francisco Bay area. We expect that Atlanta and Monterrey centers will both be opened before the end of the year, as site selections are complete, equipment has been ordered, staffing is ramping up, and marketing plans are in place. A San Francisco Bay area center should be opened shortly thereafter and our ongoing discussions with additional partners remain active. This is an exciting time for INVO as we have diversified our business model beyond device sales exclusively through our distributors, to a model where we will capture a share of the larger revenue generated by the entire INVO patient solution."

Shum concluded, "Our goal to democratize fertility treatment by bringing care to the vast underserved patient population around the world experiencing infertility challenges is advancing.  We believe a key to this effort will also involve leveraging the OB/GYN community.  In July, we appointed Dr. Barbara Levy as our SVP, global clinical integration. Dr. Levy is considered one of the most influential fertility and reproductive health clinical executives in the world and brings a life-long passion to improving women's health recognizing that a critical component to that is treatment for infertility. I am excited to have Dr. Levy help lead this OB/GYN strategy moving forward."

Financial Results

Revenues for the three months ended June 30, 2021 were approximately $0.21 million, compared to approximately $0.25 million for the same three-month period in 2020. The slight change was the result of a decrease in product sales to Ferring. Ferring's minimum purchase requirements are based on a calendar year and hence contribute to quarterly fluctuations. Revenue pertaining to the Company's INVO Centers will begin to be recognized in the current, third quarter.

Gross margin reported for the three months ended June 30, 2021 was approximately 93% compared to approximately 91% for the three months ended June 30, 2020.

Selling, general and administrative expenses for the three months ended June 30, 2021 were approximately $2.0 million compared to approximately $1.3 million for the three months ended June 30, 2020. The increase was primarily the result of increased personnel, board and business development consulting expenses, as well as startup costs related to our INVO Centers. We incurred approximately $0.6 million of non-cash, stock-based compensation expense in the period compared to $0.3 million for the same period in the prior year.

We began to fund additional R&D efforts in 2020 as part of our 5-day label expansion efforts. R&D expenses were $0.03 million for the three months ended June 30, 2021, compared to $0.03 million for the three months ended June 30, 2020.

Interest expense and financing fees were approximately $0.09 million for the three months ended June 30, 2021, compared to approximately $0.26 million for the three months ended June 30, 2020.

Net loss for the three months ended June 30, 2021 was approximately $(1.8) million compared to approximately $(1.3) million for the three months ended June 30, 2020. The increase in net loss was due to increased operating expenses.

Adjusted EBITDA (see Adjusted EBITDA Table) for the three months ended June 30, 2021 was $(1.3) million, compared to adjusted EBITDA of $(0.8) million for the three months ended June 30, 2020.

As of June 30, 2021, the Company had approximately $6.6 million in cash compared to approximately $8.4 million on March 31, 2021.

Use of Non-GAAP Measure

Adjusted EBITDA is a non-GAAP measure. This measure is not intended to be a substitute for those financial measures reported in accordance with GAAP. Adjusted EBITDA has been included because management believes that, when considered together with the GAAP figures, it provides meaningful information related to our operating performance and liquidity and can enhance an overall understanding of financial results and trends. Adjusted EBITDA may be calculated by us differently than other companies that disclose measures with the same or similar terms. See our attached financials for a reconciliation of this non-GAAP measure to the nearest GAAP measure.

Conference Call Details

INVO Bioscience has scheduled a conference call for Monday, August 16, 2021, at 4:30 pm ET (1:30 pm PT) to review these results and recent events. Interested parties can access the conference call by dialing (833) 756-0861 or (412) 317-5751 or can listen via a live Internet webcast at  https://www.webcaster4.com/Webcast/Page/2162/42110, which is also available in the Investor Relations section of the Company's website at https://www.invobioscience.com/investors/.

A teleconference replay of the call will be available through August 23, 2021 at (877) 344-7529 or (412) 317-0088, confirmation #10158496. A webcast replay will be available in the Investor Relations section of the Company's website at https://www.invobioscience.com/investors/ for 90 days.

About INVO Bioscience

We are a medical device company focused on creating simplified, lower-cost treatments for patients diagnosed with infertility. Our solution, the INVO® Procedure, is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell®, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell® is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase the availability of care. For more information, please visit http://invobioscience.com/

Safe Harbor Statement

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

INVO BIOSCIENCE, INC.
CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
		June 30, 2021			December 31, 2020
ASSETS
Current assets
Cash	$	6,643,080		$	10,097,760
Accounts receivable		47,869			21,699
Inventory		250,784			265,372
Prepaid expenses and other current assets		289,843			157,700
Total current assets		7,231,576			10,542,531
Property and equipment, net		127,151			132,206
Capitalized patents, net		22,155			5,427
Lease right of use		1,419,925			79,319
Trademarks		107,287			89,536
Notes receivable		881,827			-
Other assets		-			240
Investment in joint ventures		141,267			98,084
Total assets	$	9,931,188		$	10,947,343
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable and accrued liabilities, including related parties	$	306,252		$	328,927
Accrued compensation		349,658			527,326
Deferred revenue, current portion		714,286			714,286
Lease liability, current portion		96,921			22,707
Note payable – Payroll Protection Program		-			157,620
Convertible notes, net		249,936			536,063
Income taxes payable		-			1,062
Total current liabilities		1,717,053			2,287,991
Lease liability, net of current portion		1,355,323			58,634
Deferred revenue, net of current portion		2,500,000			2,857,143
Deferred tax liability		469			469
Total liabilities		5,572,845			5,204,237
Stockholders' equity
Common Stock, $.0001 par value; 125,000,000 shares authorized; 10,459,035 and 9,639,268 issued and outstanding as of June 30, 2021 and December 31, 2020, respectively		1,046			964
Additional paid-in capital		40,864,011			37,978,224
Accumulated deficit		(36,506,714)			(32,236,082)
Total stockholders' equity		4,358,343			5,743,106
Total liabilities and stockholders' equity	$	9,931,188		$	10,947,343

 

INVO BIOSCIENCE, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
		For the Three Months Ended June 30,						For the Six Months Ended June 30,
			2021			2020			2021			2020
Revenue:
Product revenue		$	29,900		$	67,500		$	535,852		$	147,500
License revenue			178,572			178,572			357,143			357,143
Total revenue		$	208,472		$	246,072		$	892,995		$	504,643
Cost of goods sold:
Production costs			12,163			18,739			72,477			46,301
Depreciation			2,432			2,431			4,863			4,863
Total cost of goods sold			14,595			21,170			77,340			51,164
Gross profit			193,877			224,902			815,655			453,479
Operating expenses
Selling, general and administrative			2,049,422			1,252,939			4,164,725			2,847,985
Research and development			31,016			34,890			97,283			64,940
Total operating expenses			2,080,438			1,287,829			4,262,008			2,912,925
Loss from operations			(1,886,561)			(1,062,927)			(3,446,353)			(2,459,446)
Other income (expense):
Other income			159,126			-			159,126			-
Interest income			2,425			-			4,438			-
Interest expense			(91,125)			(259,954)			(986,351)			(307,827)
Foreign currency exchange  loss			(1,028)			-			(1,492)			-
Total other income (expense )			69,398			(259,954)			(824,279)			(307,827)
Loss before income taxes			(1,817,163)			(1,322,881)			(4,270,632)			(2,767,273)
Provision for income taxes			-			-			-			-
Net loss		$	(1,817,163)		$	(1,322,881)		$	(4,270,632)		$	(2,767,273)
Net loss per common share:
Basic		$	(0.17)		$	(0.27)		$	(0.42)		$	(0.56)
Diluted		$	(0.17)		$	(0.27)		$	(0.42)		$	(0.56)
Weighted average number of common shares outstanding:
Basic			10,444,150			4,932,942			10,167,624			4,925,469
Diluted			10,444,150			4,932,942			10,167,624			4,925,469

 

	Adjusted EBITDA
		Three Months Ended				Six Months Ended
		June 30				June 30
		2021		2020		2021		2020
Net Loss		$                (1,817,163)		$                 (1,322,881)		$                (4,270,632)		$                 (2,767,273)
	Other Income	(159,126)		-		(159,126)		-
	Interest expense	9,707		(2,991)		44,778		44,882
	Foreign currency exchange  loss	1,492		-		1,492		-
	Stock-based compensation	235,144		65,309		427,208		406,772
	Stock option expense	384,083		214,915		760,606		596,390
	Amortization of debt discount	76,980		223,027		937,135		262,945
	Depreciation and amortization	(2,695)		(2,551)		5,959		5,958
Adjusted EBITDA*		$                (1,271,579)		$                    (825,172)		$                (2,252,580)		$                 (1,450,326)

*Adjusted to also include non-cash, stock-based expensing

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/invo-bioscience-reports-second-quarter-2021-financial-and-operating-results-and-provides-business-update-301356114.html

SOURCE INVO Bioscience, Inc.

FAQ

What were the financial results for INVO Bioscience in Q2 2021?

INVO Bioscience reported revenues of $208,472 for Q2 2021, down from $246,072 in Q2 2020, with a net loss of approximately $(1.8) million.

What operational milestones did INVO Bioscience achieve in Q2 2021?

INVO Bioscience opened its first U.S. INVO Center in Birmingham, Alabama, and signed a joint venture to establish an INVO Center in Atlanta.

Who was appointed as the new CFO of INVO Bioscience?

Andrea Goren was appointed as CFO of INVO Bioscience, replacing the previous outside CFO consulting firm.

What is the expected impact of the new INVO Centers on revenue?

Revenue from the newly opened INVO Centers is expected to be recognized starting in Q3 2021.

How much cash did INVO Bioscience have as of June 30, 2021?

As of June 30, 2021, INVO Bioscience reported a cash position of approximately $6.6 million.